Simultaneous cortisol/insulin microchip detection using dual enzyme tagging.

No prior work had resolved the challenge of measuring two distinct metabolic hormones simultaneously on a single miniaturized platform. Current diagnostic approaches often require separate testing procedures for insulin and cortisol, which complicates rapid clinical decision-making. This limitation hinders the development of more responsive automated glucose delivery systems for patients. Researchers have long sought to integrate multiple sensing modalities into one compact device to streamline monitoring. That uncertainty drove the creation of a dual-purpose sensor capable of handling different immunoassay formats. Previous studies focused on single-analyte detection, leaving a significant gap in multi-marker monitoring capabilities. This gap motivated the design of a device that combines sandwich and competitive assays. The current investigation addresses this need by providing a unified solution for tracking these interconnected biomarkers.

The study aims to develop a dual electrochemical immunosensor microchip for the simultaneous detection of insulin and cortisol biomarkers. This research addresses the need for improved glucose regulation in patients requiring automated insulin delivery. Current methods often lack the ability to monitor these two critical hormones together in a rapid, decentralized manner. The authors seek to overcome this limitation by integrating different enzymatically-tagged immunoassay formats onto a single platform. They hypothesize that combining sandwich and competitive assays will allow for accurate, interference-free measurement of both analytes. The motivation is to provide a tool that facilitates frequent testing for better glycemic control. By creating a unified chip, the researchers intend to simplify the diagnostic workflow for diabetes management. This project focuses on demonstrating the feasibility of this integrated sensing approach in complex biological samples.

The research team developed a microchip platform incorporating two distinct immunoassay formats. They utilized a sandwich assay configuration for insulin detection and a competitive assay for cortisol. Horseradish peroxidase served as the label for insulin, while alkaline phosphatase acted as the tag for cortisol. The investigators performed systematic optimization of incubation times to ensure high analytical performance. They employed amperometric detection to quantify the enzymatic activity on the chip surface. The team tested the device using untreated serum samples to evaluate its practical utility. They measured the performance by analyzing the signal output from a single microliter droplet. The entire procedure was designed to complete the detection process in less than 25 minutes.

The dual-marker platform successfully detected insulin and cortisol simultaneously without any apparent cross-talk between the signals. The system achieved picomolar sensitivity for insulin and nanomolar sensitivity for cortisol within a single microliter sample. Testing in untreated serum confirmed the reliability of the device under realistic conditions. The total analysis time for both biomarkers remained below 25 minutes. Optimization of the enzymatic tagging and amperometric parameters proved effective for maintaining distinct signals. The results demonstrate that integrating different assay formats on one chip is technically feasible. This approach provides a high level of analytical performance for both markers. The findings validate the potential of this microchip for rapid, decentralized metabolic monitoring.

The authors propose that their dual-marker platform offers a viable path toward decentralized metabolic monitoring. This device enables the rapid assessment of insulin and cortisol within a single small sample volume. The researchers suggest that integrating these measurements could support tighter glycemic control in clinical settings. Their findings indicate that the system functions effectively without interference between the two distinct detection pathways. The team highlights the potential for this technology to improve diabetes management through more frequent testing. They conclude that the optimized incubation and amperometric approach ensures reliable performance in untreated serum. This work demonstrates the feasibility of combining different immunoassay formats on one microchip. The study provides a foundation for future advancements in automated insulin delivery systems.